In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Ocular Therapeutix (OCUL – Research Report), with a price target of $34.00. The company's shares closed last Monday at $11.10, close to its 52-week low of $9.11. According to TipRanks.com, Wolleben is a 3-star analyst with an average return of 10.3% and a 42.3% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Clearside Biomedical, Intercept Pharma, and Altimmune. Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $26.33. See today’s analyst top recommended stocks >> The company has a one-year high of $24.30 and a one-year low of $9.11. Currently, Ocular Therapeutix has an average volume of 750.9K. Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OCUL in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA. Read More on OCUL: Robinhood Stock Faces Headwinds as SEC Weighs in Humanigen Stock to $28? This Analyst Thinks So Why TSMC Stock Might Be Worth a Look NIO Stock: Good Valuation Relative to Growth Crocs: Amazing Growth Story with More Upside Ahead The post JMP Securities Thinks Ocular Therapeutix's Stock is Going to Recover appeared first on TipRanks Financial Blog.